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Risk assessmentAssessing ambient exposure to chemical stressors often begins with time-consuming and costly monitoring
studies to establish environmental occurrence. Both human and ecological toxicology are currently challenged
by the unknowns surrounding low-dose exposure/effects, compounded by the reality that exposure undoubted-
ly involves mixtures of multiple stressors whose identities and levels can vary over time. Long absent from the
assessment process, however, is whether the full scope of the identities of the stressors is sufﬁciently known.
The Matthew Effect (a psychosocial phenomenon sometimes informally called the “bandwagon effect” or
“iceberg effect,” among others) may adversely bias or corrupt the exposure assessment process. The
Matthew Effect is evidenced by decisions that base the selection of stressors to target in environmental
monitoring surveys on whether they have been identiﬁed in prior studies, rather than considering the pos-
sibility that additional, but previously unreported, stressors might also play important roles in an exposure
scenario. The possibility that the Matthew Effect might inﬂuence the scope of environmental stressor
research is explored for the ﬁrst time in a comprehensive case study that examines the preponderance of
“absence of data” (in contrast to positive data and “data of absence”) for the environmental occurrence of
a very large class of potential chemical stressors associated with ubiquitous consumer use— active pharmaceu-
tical ingredients (APIs). Comprehensive examination of the published data for an array of several hundred of the
most frequently used drugs for whether their APIs are environmental contaminants provides a prototype exam-
ple to catalyze discussion among themany disciplines involvedwith assessing risk. The ﬁndings could help guide
the selection of those APIs that might merit targeting for environmental monitoring (based on the absence of
data for environmental occurrence) as well as the prescribing of those medications that might have minimal
environmental impact (based on data of absence for environmental occurrence).
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.; EPA, U.S. Environmental Pro-
ystem; MEOC, Matthew Effect
centration.
.V. Open access under CC BY-NC-SA l1. Introduction/background
Historically, the spectrum of chemical stressors considered in risk as-
sessments has been narrowly restricted to regulated priority and legacy
pollutants and associated conventional chemicals, such as high-volume
commercial products or those unintentionally produced as ubiquitous
by-products from industrial processes (Daughton and Ternes, 1999).
These numbers are comparatively few, however, among the tens of
thousands in widespread commercial use, without even consideringicense.
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arations — the APIs.
This tendency of comparatively few, select chemicals to occupy
the attention of the many disciplines involved in risk assessment
has been noted over the last decade, even in light of the more expan-
sive perspective on environmental contamination afforded by the
so-called “emerging” contaminants (such as APIs). A disparity in the
scope of data from environmental monitoring continues to grow as
a result of the comparatively few chemical stressors that are targeted.
This phenomenon has been deemed a manifestation of a self-fulﬁlling
selection bias referred to as the “Matthew Effect” — where the prom-
inence of those few chemicals targeted for investigation is dictated
largely by the attention devoted to them in the past. The Matthew Ef-
fect as a psychosocial phenomenon was ﬁrst articulated by Robert
Merton in his well-known work in 1968 (Merton, 1968) and later
used by Grandjean et al. (2011) to explain the biased path followed
by many of the incremental and repetitive ﬁndings of environmental
science.
The psychology involved with the conduct of science (speciﬁcally
the Matthew Effect) is largely unexplored as a factor that drives the
direction of science while creating unrecognized (stealth) bias and
uncertainty. At least one aspect of the Matthew Effect is a cognitive
bias called “availability bias” (or “availability heuristic”), which can
elicit an overestimation of risk or probability associated with an
event the more easily and vividly the event (or a similar event) can
be recalled. Events that are more easily recalled are more susceptible
to being viewed as risky or probable. This in turn further impairs the
already reduced focus on those events that are not easily recalled. In
this manner, attention tends to become devoted to events (in this
case, chemicals occurring as environmental contaminants) that are
more familiar, while the majority becomes relegated to obscurity.
Although some of the potential ramiﬁcations of the Matthew Ef-
fect in environmental science have been discussed by Grandjean et
al. (2011), evidence of it playing a possible role in introducing bias
has never been actively sought. After all, establishing an absence of
published data for a particular subject is clearly an onerous task de-
manding rigorous and time-consuming examination of as much of
the published literature as possible. Trying to establish that some-
thing has not been reported is usually perceived as a thankless en-
deavor and may explain why the Matthew Effect (if indeed an
active phenomenon) could escape notice. Perhaps the only published
example that the Matthew Effect may be at play in environmental sci-
ence comes from a 2013 study that examined the potential impact of
medication prescribing practices on environmental contamination by
APIs (Daughton and Ruhoy, 2013). Data were presented (Table S1,
therein) showing a select group of APIs that are prescribed frequently
and whether evidence exists that they also occur in the environment
as contaminants. Among the 53 frequently prescribed APIs subject of
that evaluation, minimal evidence existed in the published literature
for whether roughly a dozen had ever been targets of environmental
monitoring (an absence of data as opposed to data of absence or “ev-
idence of absence”). This absence of environmental occurrence data
for 22% of a small sampling of 53 commonly used medications indi-
cated the possibility of a substantially greater incidence of the ab-
sence of data for the much larger universe of the thousands of
distinct APIs in use today. Also note that even the limited data pub-
lished for the remainder of these APIs may have little relevance to in-
dicating overall environmental presence, as many of these data do not
result from formal monitoring surveys but rather are generated from
a select few, convenient real-world samples analyzed in the course of
developing and testing an analytical method for chemical analysis.
1.1. The Matthew Effect — contributor to uncertainty in assessing risk
Given the unknown numbers of yet-to-be-identiﬁed xenobiotics
that may play roles in the totality of biological exposure, it is criticalthat the select few that are targeted for environmental or biological
monitoring serve as sufﬁcient proxies for assessing risk. With the in-
creasing sophistication of analytical chemistry, the “iceberg” scenario
has become more evident (Daughton, in press) — where escalating
numbers of unique chemicals may be present at ever-lower, and
often immeasurable, concentrations. Emerging is evidence that col-
lections of chemicals remaining unidentiﬁed (e.g., see: Tang et al.,
2013) may hold the predominant share of overall total biological
stress in some exposure scenarios (e.g., Escher et al., in press). The
implications of the iceberg scenario can be exacerbated by the
Matthew Effect — as the risk posed by chemicals currently not mea-
sured is effectively shielded from examination or evaluation.
The critical importance of exposure assessment and its role as the
weak link in both ecological and human health risk assessment is
made clear in the European Commission's 2012 report “Addressing
the NewChallenges for Risk Assessment” (SCENIHR et al., 2012 [8 Octo-
ber]). Notably, however, this report (like all prior evaluations of the risk
assessment paradigm) perpetuates an extremely limited and biased
view of the chemical space occupied by chemical stressors. The report
does not entertain the question as to whether the universe of stressors
is sufﬁciently known, nor does it recognize the potential for bias and
data disparity by ignoring those chemical stressors lacking sufﬁcient en-
vironmental occurrence data. After all, these stressors represent that
portion of potential exposure which is stealth or masked — exposure
that is unknown but not recognized as such.
This same oversight is evident in the recent US GAO (2013) report
and the Institute of Medicine (IOM) report “Environmental Decisions
in the Face of Uncertainty” (IOM, 2013), where the IOM was request-
ed by the U.S. Environmental Protection Agency (EPA) to provide
guidance on managing risk in the face of uncertainty. While the pos-
sibility of bias and uncertainly introduced by the Matthew Effect was
not alluded to in the IOM report, an argument could be made that the
Matthew Effect should be addressed on the basis of two of the ques-
tions posed in the charge to the IOM:
(1) “How does uncertainty inﬂuence risk management under dif-
ferent public health policy scenarios?”
(2) “Are there other ways in which the EPA can beneﬁt from
quantitative characterization of uncertainty?”
Two of the recommendations made by the IOM report that were
elicited by these questions were:
(1) “To better inform the public and decision makers, EPA decision
documents and other communications to the public should
systematically … include information on what uncertainties
in the health risk assessment are present…”
(2) “EPA should develop methods to systematically describe and
account for uncertainties in decision-relevant factors…”
A methodology that facilitates a formal evaluation of whether the
Matthew Effect might be actively biasing a risk assessment could at
least in part address these two recommendations.
1.2. Goals and objectives
Presented here is an approach for assessing the potential impor-
tance of those chemical stressors that are essentially ignored because
of selective focus on the few stressors that repeatedly attract atten-
tion due to the Matthew Effect. One objective is to examine a poten-
tial vulnerability in assessing exposure: the failure to evaluate
chemicals orphaned by the Matthew Effect and the absence of data
(absence of evidence). Here, the stressors that are orphaned by the
Matthew Effect are termed “Matthew Effect Orphaned Chemicals”
(MEOCs). A case study is used to: (i) deﬁne the scope of MEOCs that
might exist for a diverse class of potential chemical stressors (using
a case study encompassing the environmental contaminants originat-
ing from pharmaceutical usage — the APIs), (ii) develop a strategy for
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sure, and (iii) raise awareness of the Matthew Effect and catalyze dis-
cussion on identifying and overcoming the Matthew Effect among
those involved with all aspects of ecological and human health risk
assessment. With a less-biased approach to selecting those stressors
that should be considered for environmental monitoring, the integri-
ty and credibility of exposure assessments could be improved and un-
certainty could be reduced. The ultimate objective is to steer attention
by researchers and regulators toward identifying those classes or
individual chemicals that are currently ignored but which may play
important roles in biological exposure — striving to achieve more
holistic exposure assessments.
A case study is used to demonstrate the potential incidence of
MEOCs among environmental contaminants. Its focus is on APIs derived
from routine pharmaceutical usage. Examinations of API environmental
occurrence data rarely attempt to systematically establish the absence
of data. APIs were selected as a test case for examining the potential
prevalence of the Matthew Effect for the following reasons:
(1) a large published literature exists on the occurrence and mon-
itoring of APIs in a wide variety of environmental compart-
ments and matrices;
(2) ready availability of a comprehensive bibliographic database of
documents relevant to the many aspects of APIs as environmen-
tal contaminants (this database greatly facilitates full-text Bool-
ean searches and maximizes coverage of both the published,
in-press, and gray literature, including over 14,000 journal arti-
cles, book chapters, reports, and dissertations) (Daughton and
Scuderi, 2013);
(3) data on relative usage rates of APIs is readily available (such as
the top 100 or 200most frequently prescribed drugs); this allows
the targeting of the most widely used APIs – among the roughly
9000 now known to be in commercial use (Huang et al., 2011) –
which therefore should be among those with high probabilities
of gaining entry to the environment; also see the discussion on
the number of distinct APIs in use today in Daughton (in press);
(4) APIs are exempt from the EU's REACH program (Holzer, 2010),
which may increase the odds that environmental occurrence
data are absent (because of a lack of incentive to obtain these
data); and
(5) ongoing and repetitive investment of research resources may be
needlessly wasted in a range of fate and toxicity studies for APIs
that have not yet been targeted for environmental monitoring
but which have a low probability of occurring in the environ-
ment (examples can be seen in Table 3, which is introduced
and explained in Section 4). For these APIs, low priority might
be given for fate and toxicity studies.
1.3. Liabilities and vulnerabilities associated with the Matthew Effect
Historically, the preferential reporting of positive versus negative
(non-positive) data has troubled a number of disciplines — one in
particular being risk assessment (Bufﬂer, 1989). The concern has
been whether publications sometimes omit the documented absence
of adverse health effects as a result of a bias, whether resulting simply
because such results are perceived as “uninteresting,” suspect, or fail
to support a hypothesis. Even though the recognition of the value of
negative results has grown (and they ﬁgure prominently in debates
surrounding subtle, low-dose effects), the two types of data provide
only two perspectives on what is knowable — essentially yes–no an-
swers to whatever questions are under investigation. A third perspec-
tive is equally important and that is whether the correct questions are
being posed or whether a sufﬁciently comprehensive suite of vari-
ables probed. This perspective can remain hidden when bias concen-
trates the focus on previously demonstrated interesting or widely
recognized ﬁndings.Assessing the risks posed by chemicals as environmental contam-
inants requires ﬁrst establishing parameters surrounding their pres-
ence in the environment (including locations, matrices, levels, and
spatiotemporal distributions and ﬂuctuations). For certain chemicals,
however, these data can be completely lacking. The extent and mag-
nitude of this deﬁciency can be unknown and, at the time, not recog-
nized as such (so-called “unknown unknowns”). Worse is that no
mechanism is in place to rectify this vulnerability.
One of a number of speciﬁc examples thatmight exhibit bias from the
Matthew Effect involves EPA's Integrated Risk Information System, IRIS
(US EPA, 2013b), which is generally recognized as a deﬁnitive, authorita-
tive technical resource for assessing health effects, albeit for a limited
number of chemicals used in – or resulting from – commerce; another ex-
ample is the EPA's Chemical Data Reporting (CDR) database (US EPA,
2013a).
An unintended consequence of this recognition is that the absence
from IRIS of a particular chemical can be misconstrued as evidence that
it may not play a meaningful role as a stressor in exposure (e.g., see:
Gray and Cohen, 2012). Such erroneous inferences result when the ab-
sence of data is conﬂated with evidence of absence. This is an example
of “availability bias.” Indeed, this is one of the tactics used in the
so-called “Four Dog Defense” — where “my dog has the ability to bite,
but it would never bite you” (Sass and Rosenberg, 2011 [October]). Or
in other words, a chemical might pose a hazard, but concern is not
warranted if the chemical is not present in the environment (a false
assertion when based on an absence of data rather than on sufﬁcient
data of absence). In reality, when a chemical is not accommodated in
IRIS, one possible cause is that it may actually prove to be a MEOC.
Indeed, with the National Research Council's ongoing review of
the IRIS assessment development process (NRC, 2013), the focus
has been devoted to ensuring that health-effect literature searches are
comprehensive for the chemicals that are under examination. But the
solicitation and selection processes used for IRIS to accommodate new
chemicals (US EPA, 2012a) may serve to preempt consideration of
chemicals for which there are no data (which necessarily might include
MEOCs); the selection assessment criteria all rely on whether data al-
ready exist for a candidate chemical. A half-dozen or so criteria are
used to justify selection of the comparatively few chemicals targeted
for IRIS. This selection process inadvertently serves to reinforce the
deﬂection of attention from the vast numbers of chemicals that are
ﬁltered from consideration to include in IRIS. A major outcome of
this self-selection bias is that chemicals that have long been ignored
(e.g., for inclusion in IRIS) risk being perpetually ignored; whether
justiﬁably or not is unknown.
Quality control safeguards do not exist to force examination of why
data for certain chemicals known to experience signiﬁcant commercial
usage might be totally absent from the literature. Such feedback loops
could ensure that chemicals are examined for whether they lack envi-
ronmental occurrence data – and therefore pose an unknown potential
for exposure – and that those posing themost risk are comprehensively
prioritized for inclusion. When data are indeed totally absent, a feed-
back loop could force conjectures or hypotheses as to whether the po-
tential for risk might need to be examined. With this in mind, once
possible MEOCs are identiﬁed, two additional lists could be created to
augment databases such as IRIS. One list could comprise MEOCs that
probably pose insigniﬁcant risks and another for those MEOCsmeriting
further examination.With access to these two additional lists, end users
of databases such as IRIS would be better informed as to what the ab-
sence of a chemical from the database might actually mean. Worth not-
ing is that some programs, such as the EPA's Unregulated Contaminant
Monitoring Rule (US EPA, 2012b), do attempt to secure occurrence data
for certain chemicals (albeit limited numbers) that may pose exposure
risks. By continually compiling and reﬁning lists of potential MEOCs,
protocols could be established to rule them in or out as environmental
contaminants and also avoid the formulation of misleading conclusions
by end-users.
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actually contaminate the environment (a subset of the universe of
potential chemical contaminants) could lead to ﬂawed life cycle
sustainability assessments. This is especially true when the chemical
itself is an ultimate commercial product as opposed to a by-product
from other anthropogenic or natural processes. For these chemicals,
sustainability proxy measures (such as carbon footprints) may not
sufﬁce in performing life cycle assessments (Laurent et al., 2012).
Using APIs as the example, incomplete knowledge of the environ-
mental occurrence of all APIs within a given therapeutic category
would prevent informing rational prescribing decisions for directing
the selection of those APIs that are least problematic regarding envi-
ronmental impact (Daughton and Ruhoy, 2013).
In general, publisheddata of any kind–whether positive or negative–
tends to strongly inﬂuence subsequent research, which, in turn, leads to
renewed focus on incrementally extending priorwork. Chemicals that re-
ceive no attention (those lacking any environmental data) are at risk of
eventually being relegated to obscurity. Focusing on incremental ad-
ditions to existing knowledge can result in non-optimal investment
of resources and lead to biased or erroneous conclusions regarding
measures of risk or sustainability. Most importantly, the magnitude
of a possible vulnerability in risk assessment posed by MEOCs may
demonstrate that efforts focused on sustainable use of chemicals
may not recognize that they are aiming at partially obscured targets
– or worse yet – the wrong targets.
Positive environmental occurrence data and data of absence (levels
below detection — negative data), by themselves alone, may provide a
highly biased view of the potential for exposure. Positive occurrence
data may perpetuate continued biased attention because of availability
bias. In contrast, identifying that which is absent from the published
literature serves to better deﬁne uncertainty, minimize data disparity,
and improve credibility. With a framework to guard against the
Matthew Effect and to reapportion focus on MEOCs, a number of posi-
tive outcomes are made possible. These include: (i) reducing unneces-
sary duplication of future effort by avoiding replicate studies on the
same, favored monitoring targets, (ii) identifying new targets for mon-
itoring (expanding the chemical space known to be occupied by poten-
tial stressors), (iii) assessing why MEOCs have not been previously
targeted, (iv) using the incidence of MEOCs as a measure of a research
ﬁeld's maturity, (v) preventing misinterpretation of the absence of
certain chemicals from various databases (such as IRIS) as being equiv-
alent to a lack of any imperative for concern regarding risk, (vi) eventu-
ally using occurrence data for chemicals that used to be MEOCs to
ground truth predictive models, and, most importantly, (vii) determin-
ing if speciﬁc exposure risks are being overlooked; progress with the
last point can be augmented with parallel studies involving biological
effects-directed studies (e.g., Blasco and Picó, 2009).
2. Methods
Establishing the absence of data for a particular API requires com-
prehensive examination of the published literature using search
strategies that are more exhaustive, onerous, and time consuming
than those that would ordinarily be used to locate positive (and
sometimes negative) occurrence data. The data source used for the
searches in this study is a comprehensive full-text bibliographic data-
base maintained at the US EPA (Daughton and Scuderi, 2013) using
EndNote X6 (Thomson Reuters). This database focuses exclusively
on the many aspects of pharmaceuticals as environmental contami-
nants (one aspect of which is environmental occurrence data). Its
scope and coverage are described here: http://www.epa.gov/ppcp/
pdf/Synopsis-of-PPCPs.pdf. The database is updated and curated on
a daily basis. Its scope spans the published archival literature,
in-press articles, and the gray literature, with coverage dating back
to the 1970s, which coincides with the advent of concerted study of
pharmaceuticals in the environment. All documents added to thedatabase are examined to ensure their contents are digitized; when
the main bodies of documents comprised scanned images, they
were digitized using Adobe Acrobat X Professional.
For each of more than 200 of themost widely prescribed or sold APIs
(see the footnotes in Supplementary Table S1 for citations to the two lists
used in this study — drugs still on-patent and generics), comprehensive
and exhaustive queries were performed to ascertain whether environ-
mental occurrence data existed (both positive and negative) and for
which particular environmental compartments (e.g., sewage, sediments,
ambient waters, biosolids, and aquatic tissues). Note that some APIs are
accounted for in redundant entries among the two lists — serving as ac-
tive ingredients in multiple drugs; many of the APIs in the brand-name
list were also on the generic list.
In compiling these data, no attempt wasmade to assess data quality
or the reliability of the studies; indeed, an unknown portion of these
data may have been ﬂawed. In particular, no attempt was made to
assess or record the analytical limits of detection (LODs) associated
with negative data (when available); the power of negative data in
establishing the absence of a targeted API increases as the LODs are
lowered.
Once it was clear that occurrence data (either positive or negative)
for a given API could be easily located, continued searching was termi-
nated, and the API was excluded from further consideration as a poten-
tial MEOC. Searching was continued for each API for which occurrence
data could not be found. Boolean searches (with EndNote X6) used as
many terms or identiﬁers for these APIs as possible. For those APIs lack-
ing any data in the current PPCPs database, searches were repeated
across documents newly added to the database up until the time this
manuscript was submitted for publication; newly added documents
are usually those that are in-press or newly published on-line.
Data published subsequent to this assessment would be expected to
continually reduce the numbers of APIs found to be lacking data, which
totaled 73 as of 23 May 2013 (Table S1 and its companion summary,
Table 1) for the speciﬁc and limited lists used here. This reduction
would probably only proceed gradually in the absence of a concerted
effort to capitalize on using absence-of-occurrence data to select APIs
for targeting in future monitoring studies. Continued failure to locate
API occurrence data for a particular API –with increasing effort expended
in searching – pointed to an ever-higher probability of absence of data.
While an absence of data can never be claimed with certainty, searches
were designed with the most inclusive possible criteria — for example,
using unique identiﬁers such as the CAS registry numbers (CASRN) and
themore common synonyms for API generic or trade names; in some in-
stances, unique non-English variant spellings or unique stems were also
used. The full-text document revealed by each query was then visually
examined for data pertinent to environmental occurrence. Searching
for terms such as “absence of data” or “lack of data” in association with
a particular API can locate rare instances where the authors claimed
that data had yet to be reported; this can sometimes work as a shortcut
to focus searches for identifying likely MEOCs.
There are some pitfalls in digitized text searches. Full-text searching
is compromisedwhen data aremasked in tables or illustrations that are
imbedded as graphic images that cannot be digitized; errors also occur
whenoptical character recognition is not faithful. This shows the impor-
tance of visually scanning the entirety of a document in which the
targeted API search term is found within the narrative. Supplemental,
on-line data can pose additional challenges. All search strategies will
fail when the search term is misspelled in the document or when the
document uses foreign spellings unknown at the time of the search.
Bona ﬁde data of absence reﬂects the ability of chemical analysis
to detect ever-lower levels of a chemical in a targeted environmental
matrix. It means either that a targeted chemical occurs at levels below
those that could be reliably detected or that residues of the chemical
simply do not occur in the matrix. In contrast, the absence of data re-
ﬂects a complete lack of knowledge, for whatever reason — whether
the potential presence of a chemical in the environment has been
Table 1
Summary listing of potential API MEOCs.a
No published data
(absence of data)
(33 APIs)
No published
data
(cont'd)
Minimal
published datab
(20 APIs)
Limited published
datac
(20 APIs)
Alendronate
(121268-17-5)
Olmesartan
medoxomil
(144689-63-4)
Chlorthalidoned
(77-36-1)
Allopurinol
(315-30-0)
Aripiprazole
(129722-12-9)
Ondansetrond
(99614-02-5)
Clonazepamd
(1622-61-3)
Amiodaroned
(1951-25-3)
Baclofen
(1134-47-0)
Oxybutynin
(5633-20-5)
Colchicine
(64-86-8)
Benztropined
(86-13-5)
Benazepril
(86541-75-5)
Phenazopyridined
(94-78-0)
Dicyclomined
(77-19-0)
Budesonide
(51333-22-3)
Benzonatate
(104-31-4)
Phentermine
(122-09-8)
Doxazosin
(74191-85-8)
Carvedilol
(72956-09-3)
Buspironed
(36505-84-7)
Pramipexole
(104632-26-0)
Etodolacd
(41340-25-4)
Clonidined
(4205-90-7)
Carbidopa
(28860-95-9)
Pregabalin
(148553-50-8)
Formoterol
(73573-87-2)
Divalproex
(76584-70-8)
Cefdinir
(91832-40-5)
Quinapril
(85441-61-8)
Glipizide
(29094-61-9)
Drospirenone
(67392-87-4)
Clobetasol
(25122-41-2)
Ropiniroled
(91374-21-9)
Isosorbide
(652-67-5)
Ezetimibed
(163222-33-1)
Cyclobenzaprined
(303-53-7)
Sumatriptand
(103628-46-2)
Memantine
(19982-08-2)
Felodipine
(72509-76-3)
Diphenoxylate
(915-30-0)
Terazosind
(63590-64-7)
Mometasone
furoated
(83919-23-7)
Finasterided
(98319-26-7)
Guaifenesin
(93-14-1)
Tiotropium
bromide
(186691-13-4)
Nebivolol
(99200-09-6)
Fluocinonide
(356-12-7)
Hydralazine
(86-54-4)
Tizanidined
(51322-75-9)
Nitrofurantoin
(67-20-9)
Fluticasoned
(90566-53-3)
Hydroxychloroquined
(118-42-3)
Topiramate
(97240-79-4)
Pioglitazoned
(111025-46-8)
Levetiracetam
(102767-28-2)
Lisdexamfetamine
(608137-32-2)
Quetiapined
(111974-69-7)
Meclizine
(569-65-3)
Methocarbamol
(532-03-6)
Sitagliptin
(486460-32-6)
Meloxicamd
(71125-38-7)
Montelukastd
(158966-92-8)
Spironolactone
(52-01-7)
Metoclopramided
(364-62-5)
Nabumetone
(42924-53-8)
Tamsulosin
(106133-20-4)
Norgestimate
(35189-28-7)
Nitroglycerin
(55-63-0)
Trazodoned
(19794-93-5)
Nystatin
(1400-61-9)
Valacyclovir
(124832-26-4)
Ramipril
(87333-19-5)
a Data summarized from the detailed data provided in Supplemental Table S1
(“Frequently prescribed APIs lacking environmental monitoring data: (i) absence of
data, (ii) data of absence, or (iii) reports restricted to trace levels”) for those APIs having
very limited published data on environmental occurrence. Chemical Abstracts Service
Registry Numbers (CASRN) listed in parentheses after API generic names.
b Minimal published data = maximum of 1–2 published reports showing limited pos-
itive data.
c Limited published data = maximum of 3–6 published reports showing limited posi-
tive data.
d APIs that are among the 106 highlighted byHoward andMuir (2011) as “highproduc-
tion volume pharmaceuticals that have not been detected in the environment but are es-
timated to be persistent and/or bioaccumulative.”
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to support any monitoring or because of very low modeled Predicted
Environmental Concentrations— PECs), the chemical has simply been
overlooked or omitted from targeting (e.g., MEOCs), or any number
of other, more speciﬁc reasons, including failure to report data of
absence (see Table 2).
3. Results
Those APIs for which extensive occurrence data (both negative
and positive) had been published were omitted from further
examination at the outset of the literature searches. Out of more
than 200 of the most frequently prescribed generic and trade name
drugs (during 2010–2011), many have considerable published dataon their environmental occurrence in a wide spectrum of matrices;
some random examples include the following dozen: azithromycin,
carbamazepine, ciproﬂoxacin, diazepam, diltiazem, ﬂuoxetine, hydrocor-
tisone, ibuprofen, metformin, omeprazole, paroxetine, and propranolol.
A subset of 82 APIs remained for more extensive literature evaluation
(detailed in Table S1). The complete published data that support the very
limited data in Table S1 derive fromonly 156 publications. All but three of
these referenceswere published in the last 10 years; over 71%were pub-
lished since 2010 (19 in 2013, 32 in 2012, 33 in 2011, and 27 in 2010). For
this subset of 82 APIs, it was not evident at the start whether any might
have adequate published data. A total of nine of these 82 APIs were sub-
sequently assessed as trending toward having occurrence data sufﬁcient
to exclude them from further literature examination; these were:
clopidogrel, digoxin, duloxetine, famotidine, hydroxyzine, lansoprazole,
methylprednisolone, olanzapine, and triamcinolone. The remaining 73
APIs were classiﬁed into three groups (Table 1) characterized as having:
(1) no published data (absence of data), (2) minimal published data
(maximum of one or two published reports showing limited positive
data), and (3) limited published data (maximumof three to six published
reports showing limited positive data). The respective numbers of the
original group of over 200 APIs distributed among these three groups
were 33, 20, and 20. Combined, these APIs composed a signiﬁcant portion
of the original group that comprised themost highly prescribed drugs. By
extension, it seems probable that those APIs with a lack of occurrence
data would tend to comprise an ever-larger portion of the API universe
as less-frequently prescribed drugs are assessed. Of these APIs, 14 are
noteworthy in that they had already been highlighted over as decade
ago as representative of those for which concerted environmental
monitoring had not yet been performed (Daughton, 2001; see Table II,
therein), and they have remained untargeted inmonitoring: alendronate,
amiodarone, benazepril, chlorthalidone, clonazepam, cyclobenzaprine,
doxazosin, glipizide, guaifenesin, pramipexole, quinapril, ropinirole,
spironolactone, and terazosin.
4. Discussion
Of the 73 APIs captured in Table 1, 36% (26 APIs) are among the
106 APIs highlighted by Howard and Muir (2011) as “high production
volume pharmaceuticals that have not been detected in the environ-
ment but are estimated to be persistent and/or bioaccumulative.” Of
these 26 APIs, 10 were among the 33 with no published occurrence
data, 8 were among the 20 with minimal published data, and 8
were among the 20 with limited published data.
The lack of environmental monitoring data for the vast majority of
APIs – and the overwrought focus on a select few – had ﬁrst been
noted over 10 years ago (e.g., Daughton, 2001, 2004b). The potential
occurrence of APIs that have never been targeted for monitoring in ﬁn-
ished drinking water has also been identiﬁed as a major unaddressed
question (Daughton, 2010b).
In addition to the ﬁrst direct report of APIs lacking environmental
occurrence data – published in Daughton and Ruhoy (2013) and
elaborated upon in Daughton (in press) – evidence of the Matthew Ef-
fect is indirectly alluded to in a study that examined published data
on the presence of 203 APIs across 41 countries (Hughes et al., 2013).
This latter study revealed that most of the monitoring efforts had
been devoted to just 14 of the 203APIs— amere 7% of the total targeted.
Although the failure to consider MEOCs for targeted monitoring
may often be an unconscious decision, there are instances where
the selection of APIs to target for monitoring is explicitly based solely
on those APIs that have been identiﬁed in prior studies (e.g., see: Tabe
et al., 2010).
In the ﬁnal analysis, the complete absence of occurrence data for
an API may represent one extreme in a broader distribution of occur-
rence frequencies. For many APIs, occurrence data may populate a
long tail comprising isolated reports (e.g., spread across diverse and
unique environmental sample matrices) that gradually build into a
Table 2
Factors affecting the acquisition, reporting, or corroboration of negative data or absence of data for an API in the environment.a
Cause for negative data or absence of data Ramification Example or miscellaneous notes
Analytical methodology limitations: 
Analytical limits of detection (LOD) or quantitation 
(LOQ) not sufficiently low for API to be detected or 
quantified in environmental matrices. 
Potent medications, even when highly prescribed, 
contribute relatively low, overall quantities of APIs to 
the environment because of their exceedingly low 
dosages.
Highly potent APIs (HPAPIs) (Bormett, 
2008 [1 Sept]). Potent APIs include 
hormones, certain synthetic opioids, 
and glucocorticoids; fluticasone is one 
example.
API is problematic for routine analytical methodologies. Analytical limitations: poor extraction efficiency; prone 
to matrix interferences; poor chromatography; failure to 
account for reversible conjugates.
API may be present but cannot be 
demonstrated.
API reference standard not available. Identity of tentatively identified API cannot be verified. API may be present but cannot be 
verified.
Non-homogeneity of stream flow affects sampling design. Variable dilution of sewage and surface water flows or 
impact of seasonal events can impact measured levels.
Adverse weather can not only lead to 
diluted streams, it can also impair the 
effectiveness of sewage treatment or 
natural removal processes.
Negative data is often presented in publications with  
unknown or unclear analytical figures of merit. 
LOD/LOQ often not reported. High LOD can lead to erroneous 
negative data for APIs having 
substantial environmental presence.
Idiosyncrasies of drug prescribing or usage:
Nationwide consumption data do not reflect local 
consumption−can confound data obtained from  
monitoring in locale where drug may not reflect common 
usage.
Local prescribing practices or customs may exclude 
certain APIs popular in other locales.
Most research studies involving 
monitoring restrict themselves to a  
particular geographic locale; few 
studies perform statistical sampling 
across larger regions or especially an 
entire nation.
Inter-country differences in drug prescribing and usage 
practices.
Published monitoring data for an API may come from 
countries where the frequency of prescribing for the 
parent drug is not representative of other countries.
Published monitoring data may also 
come from a country where the drug is
readily available OTC but only 
available via prescription elsewhere.
Regional disease patterns may make consumption of 
certain medications episodic, sporadic, or irregular.
Some diseases are endemic to specific locales. Others 
depend on the time of year, as affected by the weather.
Epidemics or seasonal viral infections,  
for example, can increase the 
consumption of a wide variety of 
medications.
Poor patient compliance/adherence for certain frequently
prescribed drugs can confound the interpretation of 
prescribing or usage data.
Poor compliance leads to leftover medications that are  
never consumed.
This could lead to measured 
environmental levels much lower than 
those predicted by models based on 
sales or prescribing data.
API manufactured in extremely low annual quantities. Extremely low environmental loadings even under the
most favorable scenarios, such as 100% excretion 
unchanged API.
Norelgestromin manufactured at 0.34 
kg/year as of 2004 (Besse and Garric, 
2009).
API newly introduced to market. API has not experienced sufficient usage to display 
detectable environmental loadings.
Any of the NMEsb approved by FDA 
each year.
Idiosyncrasies of drug metabolism or excretion:
Diurnal variations in excretion impact the statistical  
design of sewage sampling/monitoring.
Cyclic levels of API in discharged sewage (as well as a  
non-homogeneous matrix) necessitate sampling 
protocols that accommodate continual random and 
diurnal fluctuations in levels.
Levels in discharge can be affected by  
morning urine voids or by daily timing 
of doses.
Pharmacokinetics does not favor excretion of sufficient 
quantities of parent API.
Some APIs are extensively metabolized to inactive 
products, or reversible metabolic conjugates are not 
formed; however, environmental residues could still 
result from disposal of unwanted leftover drugs to sewers 
or trash.
Certain drugs (i.e., prodrugs) are 
designed to be rapidly converted to 
other, more active forms (which 
themselves may also serve as APIs in  
other medications).
Certain individual APIs may have multiple origins−originating 
from structurally different drugs. 
Some APIs can be created during sewage treatment via 
microbial metabolism of other APIs. Some APIs are the  
putative agent from other prodrugs.
Canrenone can be formed from either 
spironolactone or canrenoate; see 
discussion on prodrugs (Daughton,  
2013 [in press]).
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Cause for negative data or absence of data Ramification Example or miscellaneous notes
Characteristics of transport and fate:
API does not reside in environmental compartment 
targeted for monitoring.
API partitions extensively to sewage sludge or sediments 
(e.g., oxytetracycline).
Monitoring the wrong compartment 
will return negative data.
API is easily removed by conventional STPs. API undergoes facile biodegradation or partitions  
extensively to sludge/biosolids.
API cannot establish sufficient 
environmental loading. Results in true 
data of absence.
API is readily removed or transformed by ambient 
environmental processes.
Biodegradation, sorption, sequestration, hydrolysis, 
photolysis.
Formation of active or inactive 
transformation products; possible 
mineralization. Results in true data of 
absence.
Waste streams from API manufactures or formulators 
can confound data obtained from receiving waters.
Levels of a select few APIs from manufacture waste  
streams can contribute inordinately to the total 
environmental loadings relative to end use.
(Larsson et al., 2007)
API overlooked or escapes notice for any number of reasons during monitoring studies:
Newly registered NME formulated in a brand-named 
drug newly introduced to market.
API not yet considered or recognized for targeted 
monitoring. 
Some NMEs gain rapid market 
penetration and quickly ascend the 
rankings of prescribing frequency or 
usage and therefore lag in capturing 
attention for targeted monitoring.
Lack of suitable analytical method. API never targeted or targeted only in limited-scope 
laboratory research for demonstrating applicability of 
new analytical methods.
API not targeted in sufficient number of 
monitoring studies. Resulting data not 
statistically representative.
API is actively ignored as a target because it is assumed 
benign in the environment or assumed to have little 
probability of entering or persisting in the environment.
API not targeted because of fallacious assumptions 
regarding potential environmental significance 
(purported low ecotoxicity) or ability to enter the 
environment (e.g., structurally labile or extensively 
metabolized and therefore not excreted).
Knowledge regarding pharmacokinetics 
or environmental fate and transport may 
be insufficient for predicting 
environmental occurrence. Both  
bathing and disposal of leftovers to 
sewers, for example, could confound 
predicted environmental concentrations.
The Matthew Effect Overwrought focus on those APIs subject of previous 
monitoring. Those APIs never targeted for monitoring 
continue to escape targeting.
Discussed in this paper; examples first 
presented in Daughton (2013 [in 
press]).
API detected as an unknown during analysis but 
subsequent identification not attempted.
API ignored as unidentified unknown during analysis. Or 
TICs (tentatively identified compounds) never verified in 
follow-up studies.
Non-targeted analysis can be time-
consuming and costly. Analytical 
reference standard not available.
Data of absence (negative data) not reported. Occurrence data withheld from publishing can perpetuate 
the absence of data.
Author does not see value in reporting 
negative data or journal space 
limitations ultimately result in its 
censure.
Data problematic to locate, retrieve, mine, or interpret:
Data exist only in obscure reports; language translations 
not easily obtained; documents not available via the 
Internet.
Published occurrence data (either positive or negative) 
may exist but are difficult to locate or retrieve. Negative 
data is rarely of primary interest to investigators and is 
therefore not always highlighted in articles. 
Negative data published in poorly 
accessible sources (non-native 
languages and gray literature not 
available via the Internet).
Difficulties in making literature searches comprehensive. Difficult to accommodate all alternate spellings or 
unique (or arcane) synonyms for an API during literature 
searching; search engines are often limited with respect 
to full-text stemming and lemmatization capabilities. 
Documents with mis-spellings are not located. Even 
"unique" identifiers (e.g., CAS Registry Numbers - 
CASRN) are not a fully reliable search strategy because 
they can be misformatted.
Some APIs have multiple CASRN 
(e.g., isomers, polymorphs, salts, etc); 
CAS Registry Numbers are not  
uniformly employed in all publications.
Not all documents (or their content) are digitized. Data 
can remain hidden to digital searching
Full-text searching is sometimes thwarted by the fact that 
many documents are scanned images. For many digital 
documents, the search term may exist only within 
imbedded images.
Images are sometimes imbedded in 
tables, illustrations, or side-bars; these 
may not be amenable to digitization 
(e.g., angled print or characters 
presented as artwork may not be 
amenable to optical character  
recognition software).
Data from Besse and Garric, 2009; Bormett, 2008 and Larsson et al., 2007.
aMost of these issues contribute to absence of data. Very few contribute to bona ﬁde data of absence; these are highlighted with shading.
bNMEs: New Molecular Entities.
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the absence of data may therefore have to be expressed in nuanced
gradations — one example being the three subjective categories used
in Table 1.
Data of absence for environmental presence undoubtedly results for
many APIs from pharmacokinetics that favors extensive metabolism
(without subsequent formation of reversible conjugates — conjugates
that can undergo subsequent hydrolysis to reform the parent API). Like-
wise, the absence of data may sometimes result from basing decisions
to ignore certain APIs as possible monitoring targets as a result of phar-
macokinetics that minimizes excretion of parent API or reversible con-
jugates. An API may have been actively excluded from consideration
formonitoring because of a lowPredicted Environmental Concentration
(PEC) as yielded by models based on pharmacokinetics. An adverse
feedback loop may develop whereby the lack of occurrence data for
an API may encourage over-reliance on predictive models.
A major problem with establishing the absence of data is the un-
known extent to which studies might refrain from reporting evidence
of absence (e.g., negative data). At this point it is not possible to judge
whether the absence of monitoring data for certain, frequently used
APIs is because of a bona ﬁde absence of occurrence data or because of
systematic failures to report data of absence. A large number of factors
can contribute to data of absence (negative data) as well as to an
overall absence of data; some of these are probably widely recognized
(e.g., see: Oosterhuis et al., 2013). These factors are compiled in
Table 2 and fall under six general categories: (i) limitations in analytical
methodology or instrumentation; (ii) idiosyncrasies involvedwith drug
prescribing or usage; (iii) idiosyncrasies of API metabolism or excre-
tion; (iv) fate and transport characteristics; (v) failures to consider or
select APIs for targeted monitoring; and (vi) difﬁculties in locating,
mining, or interpreting published data. The Matthew Effect is provided
as an example in the ﬁfth factor (why an API has not yet been consid-
ered for targetedmonitoring). The big unknown iswhether the absence
of data (such as caused by theMatthew Effect) explains a larger portion
of missing occurrence data than does the incidence of actual, bona ﬁde
data of absence (whose contributory factors are highlighted in Table 2
by shaded cells).
Pharmacokinetic data that indicate an API is extensively excreted
unchanged (and therefore indicating its propensity to enter the envi-
ronment) can be used in conjunction with the absence of data to select
targets for future monitoring that have a high probability of being
detected. But pharmacokinetic data that shows extensive metabolism
cannot be used solely in conjunction with the absence of data to indi-
cate a lower probability of an API occurring in the environment. APIs
that are extensively metabolized must ﬁrst be evaluated for whether
they are excreted extensively as reversiblemetabolic conjugates (some-
times also called interconvertable conjugates — an example of “futile
metabolic cycling”), which can be reconverted to the parent API (also
called deconjugation, which serves to recycle the API or aglycone).
The potential role of reversible drug conjugates (including sulfate,
acyl, glucuronide, and amino acid derivatives) serving as hidden reser-
voirs for parent APIs in the environment (Daughton, 2004a) continues
to receive attention (e.g., Celiz et al., 2009). But the detailed examina-
tion of pharmacokinetic data for drugs to assess the magnitude of
conjugate excretion is extremely complex (e.g., see: Trontelj, 2012)
and has received comparatively little attention.
A basic problem is faced in evaluating the pharmacokinetic data sub-
mittedwith commercial drug registrations. These data tend to not focus
on: (i) the types and quantities of reversible conjugates of the parent
API itself or (ii) the extent to which an API passes unabsorbed and
non-metabolized through the gut and is directly excreted with the
feces. Data regarding conjugates can be particularly confusing because
it is often reported in terms of all conjugates, including those of phase
I metabolites. In reality, the primary published literature needs to be
thoroughly examined to determine these factors for each API; this can
be extraordinarily time consuming and was not attempted for thiscase study. Such literature is often very limited, with the pharmacoki-
netics of many drugs still not being sufﬁciently understood. Pharmaco-
kinetic data summaries in the secondary literature that simply state that
an API is “extensively metabolized” are insufﬁcient to rule out whether
the API has potential for occurrence in the environment via excretion.
The portion of excreted products involving the parent API needs to be
clearly stated.
Further complications result from the numerous variables that dic-
tate or regulate drug consumption and API metabolism and excretion.
Many of the complexities involved with determining whether and
how APIs enter the environment have been summarized by Daughton
and Ruhoy (2009; also see Fig. 1, therein) and Daughton and Ruhoy
(2013; see Table 4, therein). Pharmacokinetics can involve a complex
interplay of dose regimen complexity and duration, polypharmacy
(e.g., drug–drug interactions that inhibit or promote metabolism),
race, age, gender, body weight, obesity, nutritional status and food
intake, gut microbiota, health status (especially renal, hepatic, and gut
function), circadian timing of dose, dose-form modiﬁcation (e.g., split-
ting or crushing extended- or delayed-release tablets), and genetic
factors (e.g., rapid versus poor metabolizers), among others.
Excretion data from clinical trials and research are often expressed
over a deﬁned period ranging fromhours to days.Mass balance closures
are rarely achieved for dose versus excreted/retained mass. Although
such short-term data may be sufﬁcient to inform pharmacodynamics,
they do not reveal the extent of total excretion that ultimately occurs.
With respect to the ultimate environmental loading for an excreted
API, the rate of excretion is not the determinant. Instead, the determi-
nant is the overall, cumulative excretion from a given dose (regardless
of the duration of excretion).
Regardless of their pharmacokinetics, some of the APIs in Table 1
would still be expected to enter sewers directly, without undergoingme-
tabolism. Direct entry into sewers can occurwhen unwantedmedications
are disposed into drains, and bathing can release low levels of APIs that
have been excreted via sweat (Daughton and Ruhoy, 2009). More signif-
icantly, however, bathing may be the major source of release for those
APIs that are used extensively or exclusively in topical medications —
where high-content preparations are externally applied in signiﬁ-
cant quantities (Daughton and Ruhoy, 2009; see Table 3, therein).
Among the 73 APIs listed in Table 1, for example, seven are formulat-
ed extensively in topical medications: acyclovir (formed from its
prodrug valacyclovir), clobetasol, ﬂuocinonide, ﬂuticasone propio-
nate, mometasone furoate, nitroglycerin, and nystatin. Targeted
monitoring for at least these seven APIs may be warranted regardless
of PECs derived from pharmacokinetics. Indeed, examples exist of poor-
ly excreted APIs that are used in topical medications and which are also
known to occur in the environment (Daughton and Ruhoy, 2009; see
Table 4, therein).
Among the 73 APIs with potential to be classiﬁed as MEOCs
(Table 1), the most prominent category comprised 33 APIs lacking any
published occurrence data. These APIs composed the class with the
most likelihood of being MEOCs. For these, an additional evaluation
was performed to demonstrate how pharmacokinetics might be used
to further evaluate these potential MEOCs for their potential to enter
the environment. Those APIs that are extensively excreted unchanged
or extensively excreted as reversible conjugates, andwhich are also no-
table with a complete absence of occurrence data, might have the
highest potential for being MEOCs. Of these 33 APIs, a total of 20 met
this criterion (Table 3); this table summarizes the data compiled in Sup-
plemental Table S2. These 20 APIs represent those with the highest
probability of being MEOCs (in addition to those used extensively in
topical medications). These might therefore warrant targeting for envi-
ronmental monitoring. Another category in Table 3 comprises the
remaining APIs (13 in total) that are poorly excreted, which greatly
limits their ability to enter the environment other than by way of
direct disposal to sewers or via release of topical residues during bath-
ing (i.e., nitroglycerin and oxybutynin).
Table 4
Potential value of API negative occurrence data (data of absence).
Data of absence: value, utility,
advantage
Explanation
Guide the selection of APIs to be
targeted in environmental
monitoring
APIs having insufﬁcient data of absence
(i.e., absence of data) can be
cross-checked with PECs (Predicted
Environmental Concentrations) to
indicate their possibility of occurrence
(and need for further monitoring). Data
of absence reported only in particular
environmental compartments may
direct the need for monitoring in other
compartments.
Justify the exclusion of certain
APIs from future monitoring
Helps avoid duplication of effort and
expenditure of additional resources;
narrows the universe of APIs requiring
further examination (e.g., ecotoxicity);
but attention must still be paid to special
circumstances (one example being the
waters receiving treated waste streams
from a manufacturer).
Guide medical prescribing decisions for
selection of medications having a low
probability of environmental impact
APIs having sufﬁcient data of absence do
not enter the environment as a result of
intended end-use (e.g., via excretion or
bathing) or by way of disposal of
leftovers to sewers.
Ground-truth predictive models; help
avoid over-reliance on predictive
models
PECs indicating low probability of
occurrence should be corroborated with
sufﬁcient data of absence or questioned
with the absence of data.
Help guide design of environmentally
benign drugs
APIs having sufﬁcient data of absence
may have structural attributes that
reduce excretion or promote
environmental transformation/
degradation; these APIs increase the
power of structure activity relationships.
Avoid the Matthew Effect Dedicating some emphasis to acquiring
and reporting negative data may help
avoid an over-wrought and biased focus
on a limited subset of potential API
environmental contaminants and reduce
the incidence of MEOCs.
Improves completeness of monitoring
data (weight of evidence), providing
a more representative picture of
overall API occurrence in the
environment
Censoring data of absence serves to bias
the overall picture of API occurrence in
the environment; bias toward positive
ﬁndings of API occurrence in monitoring
studies (suppression of negative
ﬁndings) reduces the overall value of
monitoring.
Table 3
The 20 APIs (of 33) identiﬁed as most probable MEOCs in this study, further catego-
rized according to one measure of their potential to enter the environment —
pharmacokinetics.
Possibly increasing probability of MEOCs→
(−) (+) (++) (+++)
Benzonatate (−?) Aripiprazole Alendronate Clobetasol
Buspirone Benazepril Baclofen
Cyclobenzaprine
(−?)
Carbidopa Cefdinir
Diphenoxylate Methocarbamol (+?) Hydroxychloroquine
Guaifenesin (−?) Ondansetron (+?) Olmesartan medoxomil
Hydralazine Phentermine Phenazopyridine
Lisdexamfetamine Ropinirole Pramipexole
Montelukast (−?) Terazosin Pregabalin
Nabumetone Quinapril
Nitroglycerin Tiotropium bromide
Oxybutynin Topiramate
Sumatriptan
Tizanidine
This table contains the 33 APIs that lacked any published environmental occurrence data.
These are identiﬁed in Table 1. Supporting references for pharmacokinetic data relevant to
eachAPI are compiled in Supplemental Table S2 (“APIs identiﬁed asmost probableMEOCs
in this study, categorized according to one measure of their potential to enter the
environment — pharmacokinetics”).
Key:
(+++) = nearly stoichiometric release to sewers during bathing (APIs that are
approved for topical use only — except for portion absorbed via the skin).
(++) = substantial portion of API (or active ingredient from prodrug form) possibly
excreted unchanged or released during bathing (for topical drugs).
(+) = possibly signiﬁcant quantity of API (or active ingredient from prodrug form)
excreted unchanged or released during bathing (for topical drugs).
(?) = excretion of parent API either unknown or extent of reversible conjugates
unknown.
(−) = little excreted unchanged or as reversible conjugates.
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as potential MEOCs pertains to certain prodrugs that lack bioactivity of
their own but which release active agents that also serve as the active
ingredients in other drugs. For these prodrugs, monitoring for the re-
leased API already accounts for the prodrug's entry to the environment.
For example, among the narrowed list of 33 APIs in Table 3, four are
prodrugs (lisdexamfetamine, nabumetone, olmesartan medoxomil,
and quinapril). For one of these (i.e., lisdexamfetamine), the potential
for its entry to the environment is already being inadvertently
accounted for by monitoring for the active ingredient released from
the prodrug — in this case, dextroamphetamine.
Finally, the case study presented here used a single selection criteri-
on (i.e., likelihood of API excretion, both unchanged and in the form of
reversible conjugates) to narrow the list of all APIs lacking occurrence
data for the purpose of selecting future monitoring targets. Many addi-
tional and more difﬁcult-to-assess factors can complicate determining
the potential for an API's entry to the environment. Just because an
API might be among the most frequently prescribed or sold, coupled
with its being extensively excreted unchanged, does not necessarily
mean that itwill reach a level in the environment sufﬁcient to be detect-
ed. Most of these responsible factors are listed in Table 2. Three worth
highlighting (see: Daughton, 2010a) are: (i) prescriptions and sales do
not necessarily reﬂect ultimate drug usage (largely because of patient
non-compliance — failure to ﬁll prescriptions or to take a full regimen
of dispensed medication), (ii) drugs often experience signiﬁcant
geographic biases in usage and abrupt temporal changes in usage
(e.g., as a function of prescribing behavior and customs, consumer
demand, weather, season, epidemics), and (iii) highly potent drugs
are manufactured and consumed in very low quantities. With regard
to the ﬁrst factor, extremely complex aspects of various human
activities and behaviors surround the prescribing, dispensing, and
ultimate usage of drugs. These factors can dictate which drugs are
preferentially prescribed (which can reﬂect the knowledge, customs,
and fads of prescribers as well as marketing by manufacturers) andinﬂuence patient compliance, which determines what fraction of
prescriptions are eventually dispensed and how much of a dispensed
drug is consumed (which, in turn, determines how much leftover
drug may eventually require disposal, sometimes to sewers); some
drugs are known for signiﬁcantly lower patient compliance rates,
especially those having unpleasant side effects or which are used to
treat symptoms the patient cannot self-assess.
An API's propensity to enter the environment, however, can also be
considered in conjunction with its overall hazard (e.g., see: Dong et al.,
2013) which can manifest itself in many ways, including: (i) predictable
acute, extreme toxicity — one example being single-dose lethality in
humans (Daughton, 2010a; Daughton and Ruhoy, 2013), (ii) acute toxic-
ity in non-target species, as witnessed by renal toxicity for certain vul-
tures from ingesting NSAID residues (e.g., Oaks and Watson, 2011), and
(iii) subtle effects (Daughton and Ternes, 1999) such as alteration of
feeding, attraction, and avoidance behaviors for aquatic organisms
from chronic low-level exposures (e.g., Brodin et al., 2013; Di Poi et al.,
2013; Fong and Molnar, 2008; Fong and Hoy, 2012; Gaworecki and
Klaine, 2008; Guler and Ford, 2010; Schultz et al., 2011; Thomas and
Klaper, 2012). Additional, but more complex, aspects of toxicology also
need to be considered, most prominently being interactive and additive
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ual levels that may be substantially below their known no-effect levels.
As an addendum reﬂecting the progress in the reporting of new
data, since the cut-off date of the examination reported here (23 May
2013), an unusually large monitoring study (Chen et al., in press) re-
ports on the tentative occurrence of 11 of the APIs compiled in
Table 1.While this new study did not provide conﬁrmation of the struc-
tural identities, each of these 11 APIs were reported in the sediments of
at least one of three rivers in China at levels sufﬁcient to give
signal-to-noise ratios greater than 3 (amiodarone, hydroxychloroquine,
and ondansetron) or 10 (benazepril, buspirone, quinapril, tizanidine,
quetiapine, trazodone, glipizide, and clonidine); the six APIs shown in
italics had not yet been reported in the literature, and the remaining
ﬁve had only minimal or limited studies supporting their environmen-
tal occurrence. Although the gradual addition of new data such as these
will serve to eventually erode the existing numbers of MEOCs, new
candidates are continually added with newly approved drugs and
with revised compilations of most-frequently prescribed drugs.5. Future research and considerations
Several decades of monitoring studies have established the presence
of hundreds of APIs in a wide variety of environmental compartments
and matrices, including: treated and raw sewage (including sludge and
biosolids), animal manure, landﬁlls, surface waters, ground waters,
drinking waters, marine environments, sediments, tissues of crops and
native vegetation, tissues of aquatic and occasionally terrestrial wildlife,
manufacturer wastewaters, and air (e.g., see: Fatta-Kassinos et al.,
2011; Heeb et al., 2012; Howard and Muir, 2011; Lapworth et al., 2012;
Petrovic et al., 2008; Thomas and Langford, 2010); these hundreds,
however, represent but a small percentage of those APIs in active use
(see: Huang et al., 2011). These data are published in a bewildering spec-
trum of disparate journals, dissertations, books, reports, and other gray
literature. Despite these published occurrence data, however, no attempt
has beenmade to compile them in a publically accessible database.With
the ﬁrst comprehensive database of extant APIs, now assembled in the
National Institutes of Health (NIH) Chemical Genomics Center's Pharma-
ceutical Collection (NPC) (Huang et al., 2011), an opportunity exists
(Daughton, in press) to crosswalk this comprehensive list of known
APIs with those that have been reported in the published environmental
monitoring projects. This could provide a real-time perspective onwhich
APIs have evaded attention — the MEOCs. While construction of a com-
prehensive database on API occurrence in the environment from the
published literature would be a major undertaking, it would be amena-
ble to compilation and curation by crowdsourcing.
Likewise, it is also surprising that the yearly lists of the most wide-
ly used drugs (e.g., APIs most frequently prescribed, such as those
used for Table S1) are not periodically evaluated for those APIs that
have not yet been detected in the environment. These publically
available lists can change dramatically on a yearly basis. In real
time, prescribing and usage are in a constant state of ﬂux as a result
of many inﬂuences (e.g., see: Table 2). Access to real-time, geographic
prescribing or sales data, which is largely proprietary in the U.S. and
available only via subscription, would greatly help in maintaining
dynamic lists of APIs to examine for MEOC candidates. Examples of
geographic discrepancies, often resulting from prescribing customs
and the incidence of disease, can be seen with the data published by
Express Scripts (Cox et al., 2008) and in the work reviewed by
Wangia and Shireman (in press). Examples of geographic usage
data derived from direct sewage monitoring are most extensive for
illicit drugs; these studies reveal large geographic discrepancies in
relative usage patterns (e.g., Nefau et al., 2013; Thomas et al., 2012).
Also note that some medications are not approved for use in all
countries, and certain drugs can be withdrawn from markets in
some countries but not others.While the frequency of prescribing does not directly translate to
the mass of the API prescribed or consumed, it does translate into
those APIs whose end use probably results in better market penetra-
tion and therefore higher probabilities for detection in wastewaters
and the environment; these lists only represent but a small percent-
age (perhaps less than 5%) of the total numbers of APIs in use. APIs
lacking occurrence data should be further investigated to determine
the cause of the absence of data — whether unreported APIs have
been overlooked (casualties of the Matthew Effect) or actively
ignored (for example, because of difﬁculty in analysis). Evaluation
of published PEC and PNEC (predicted no-effect concentration) data
for each API can serve as an initial ﬁlter to select possible MEOCs to
further investigate.
With respect to pollution prevention, it is worth noting that not
only can the selection of potential API monitoring targets be guided
by the absence of data (e.g., MEOCs), but also drug prescribing deci-
sions could be guided by data of absence. Those APIs whose published
environmental occurrence data consistently show unmeasurable
levels in a sufﬁciently wide range of matrices could possibly be classi-
ﬁed as environmentally benign. Within a particular therapeutic class,
and with therapeutic efﬁcacies being similar, those APIs with negligi-
ble environmental footprints could be favored for prescribing. For this
reason, it would be useful to verify which of the highly prescribed
APIs lacking any type of environmental monitoring data actually do
have negligible environmental presence (consistent data of absence).
Other advantages are associated with data of absence (Table 4), the
incidence of which can be maximized by identifying MEOCs and
ruling them in or out as not occurring in the environment.
Finally, the case study presented here for APIs could be extended
to other classes of chemicals to determine whether MEOCs reveal
similar biases in establishing the scope of environmental monitoring
programs. With an active focus on MEOCs, a different perspective
could be gained for the prioritization of environmental contaminants
when designing targeted monitoring programs. In particular, chemicals
that are potential MEOCs should be prominently highlighted to ensure
that they do not permanently escape notice. Perhaps more impor-
tant is advancement of our understanding of how MEOCs come
about and what protocols could be established to avoid their
proliferation.
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